Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study
Summary: Background: Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes in survival over time. Methods: A retrospective, population-based study using nationally representative data between 1995 and 2018 fro...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | The Lancet Regional Health. Europe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266677622200206X |
| _version_ | 1811264932158636032 |
|---|---|
| author | Benjamin E. White Brian Rous Kandiah Chandrakumaran Kwok Wong Catherine Bouvier Mieke Van Hemelrijck Gincy George Beth Russell Rajaventhan Srirajaskanthan John K. Ramage |
| author_facet | Benjamin E. White Brian Rous Kandiah Chandrakumaran Kwok Wong Catherine Bouvier Mieke Van Hemelrijck Gincy George Beth Russell Rajaventhan Srirajaskanthan John K. Ramage |
| author_sort | Benjamin E. White |
| collection | DOAJ |
| description | Summary: Background: Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes in survival over time. Methods: A retrospective, population-based study using nationally representative data between 1995 and 2018 from the National Cancer Registry and Analysis Service (NCRAS) in England was conducted on 63,949 tumours. Age-standardized incidence was calculated using Office for National Statistics (ONS) data. Overall survival (OS) was calculated using the Kaplan-Meier estimator. Multivariable analysis was performed using an accelerated failure time model. Findings: Of 63,949 cases, 50.5% (32,309) were female. Age-adjusted incidence increased 3.7-fold between 1995 and 2018 from 2.35 to 8.61 per 100,000. In 2018, highest incidence occurred in lung (1.47 per 100,000), small intestine (1.46 per 100,000), pancreas (1.00 per 100,000) and appendix (0.95 per 100,000). In multivariable analysis, age, sex, morphology, stage, site and deprivation were independent predictors of survival (p < 0.001). Survival of the entire cohort, and by primary site, is improving over time. Interpretation: NEN incidence continues to rise in England with survival improving over time. Relatively high survival compared to other cancers is an issue for long-term outcomes and funding of care. Funding: Data were extracted and transferred using a grant from Neuroendocrine cancer UK. |
| first_indexed | 2024-04-12T20:14:39Z |
| format | Article |
| id | doaj.art-2fa2d46aca0e4e118bc1a5eab1b30d88 |
| institution | Directory Open Access Journal |
| issn | 2666-7762 |
| language | English |
| last_indexed | 2024-04-12T20:14:39Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Europe |
| spelling | doaj.art-2fa2d46aca0e4e118bc1a5eab1b30d882022-12-22T03:18:10ZengElsevierThe Lancet Regional Health. Europe2666-77622022-12-0123100510Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based studyBenjamin E. White0Brian Rous1Kandiah Chandrakumaran2Kwok Wong3Catherine Bouvier4Mieke Van Hemelrijck5Gincy George6Beth Russell7Rajaventhan Srirajaskanthan8John K. Ramage9Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, RG24 9NA, United Kingdom; Corresponding author.NHS Digital, 7 and 8 Wellington Place, Leeds, West Yorkshire, LS1 4AP, United KingdomBasingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, RG24 9NA, United KingdomNHS Digital, 7 and 8 Wellington Place, Leeds, West Yorkshire, LS1 4AP, United KingdomNeuroendocrine Cancer UK, Holly House, Leamington Spa, CV32 4JL, United KingdomTranslational Oncology and Urology Research, School of Cancer & Pharmaceutical Sciences, King's College London, United KingdomTranslational Oncology and Urology Research, School of Cancer & Pharmaceutical Sciences, King's College London, United KingdomTranslational Oncology and Urology Research, School of Cancer & Pharmaceutical Sciences, King's College London, United KingdomKing's Health Partners ENETS Center of Excellence, King's College Hospital, London, SE1 9RT, United KingdomBasingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, RG24 9NA, United Kingdom; King's Health Partners ENETS Center of Excellence, King's College Hospital, London, SE1 9RT, United KingdomSummary: Background: Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes in survival over time. Methods: A retrospective, population-based study using nationally representative data between 1995 and 2018 from the National Cancer Registry and Analysis Service (NCRAS) in England was conducted on 63,949 tumours. Age-standardized incidence was calculated using Office for National Statistics (ONS) data. Overall survival (OS) was calculated using the Kaplan-Meier estimator. Multivariable analysis was performed using an accelerated failure time model. Findings: Of 63,949 cases, 50.5% (32,309) were female. Age-adjusted incidence increased 3.7-fold between 1995 and 2018 from 2.35 to 8.61 per 100,000. In 2018, highest incidence occurred in lung (1.47 per 100,000), small intestine (1.46 per 100,000), pancreas (1.00 per 100,000) and appendix (0.95 per 100,000). In multivariable analysis, age, sex, morphology, stage, site and deprivation were independent predictors of survival (p < 0.001). Survival of the entire cohort, and by primary site, is improving over time. Interpretation: NEN incidence continues to rise in England with survival improving over time. Relatively high survival compared to other cancers is an issue for long-term outcomes and funding of care. Funding: Data were extracted and transferred using a grant from Neuroendocrine cancer UK.http://www.sciencedirect.com/science/article/pii/S266677622200206XNeuroendocrine tumourNeuroendocrine neoplasiaCarcinoidEpidemiologySurvivalIncidence |
| spellingShingle | Benjamin E. White Brian Rous Kandiah Chandrakumaran Kwok Wong Catherine Bouvier Mieke Van Hemelrijck Gincy George Beth Russell Rajaventhan Srirajaskanthan John K. Ramage Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study The Lancet Regional Health. Europe Neuroendocrine tumour Neuroendocrine neoplasia Carcinoid Epidemiology Survival Incidence |
| title | Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study |
| title_full | Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study |
| title_fullStr | Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study |
| title_full_unstemmed | Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study |
| title_short | Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study |
| title_sort | incidence and survival of neuroendocrine neoplasia in england 1995 2018 a retrospective population based study |
| topic | Neuroendocrine tumour Neuroendocrine neoplasia Carcinoid Epidemiology Survival Incidence |
| url | http://www.sciencedirect.com/science/article/pii/S266677622200206X |
| work_keys_str_mv | AT benjaminewhite incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT brianrous incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT kandiahchandrakumaran incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT kwokwong incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT catherinebouvier incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT miekevanhemelrijck incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT gincygeorge incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT bethrussell incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT rajaventhansrirajaskanthan incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy AT johnkramage incidenceandsurvivalofneuroendocrineneoplasiainengland19952018aretrospectivepopulationbasedstudy |